ArticlePloS one2013
A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- From bedside to bench: New insights in epilepsy-associated tumors based on recent classification updates and animal models on brain tumor networks.Molecular oncology · 2024Review
- FUBP1 in human cancer: Characteristics, functions, and potential applications.Translational oncology · 2024Review
- Preclinical Models of Low-Grade Gliomas.Cancers · 2023Review
- Preclinical modeling of lower-grade gliomas.Frontiers in oncology · 2023Review
- Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.International journal of molecular sciences · 2022Article
- Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Cell reports. Medicine · 2021Review
- Contemporary Mouse Models in Glioma Research.Cells · 2021Review
- Review
- Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.Acta neuropathologica · 2020Article
- Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening.Cancers · 2020Article
- Patient-derived xenografts of different grade gliomas retain the heterogeneous histological and genetic features of human gliomas.Cancer cell international · 2020Article
- PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Article
- Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways.EMBO molecular medicine · 2017Article
- Therapeutic Hypothesis Testing With Rodent Brain Tumor Models.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Glioma: experimental models and reality.Acta neuropathologica · 2017Review
- Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.Neuro-oncology · 2016Article
- A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.Journal of neuro-oncology · 2015Article
- Contemporary murine models in preclinical astrocytoma drug development.Neuro-oncology · 2015Review
- In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies.Cellular and molecular life sciences : CMLS · 2014Review
Corrections and comments
- Erratum issuedValenzuela, Jaime Alberto Campos [corrected to Campos Valenzuela, Jaime Alberto]
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligodendroglioma poses a biological conundrum for malignant adult human gliomas: it is a tumor type that is universally incurable for patients, and yet, only a few of the human tumors have been established as cell populations in vitro or as intracranial xenografts in vivo. Their survival, thus, may emerge only within a specific environmental context. To determine the fate of human oligodendroglioma in an experimental model, we studied the development of an anaplastic tumor after intracranial implantation into enhanced green fluorescent protein (eGFP) positive NOD/SCID mice. Remarkably after nearly nine months, the tumor not only engrafted, but it also retained classic histological and genetic features of human oligodendroglioma, in particular cells with a clear cytoplasm, showing an infiltrative growth pattern, and harboring mutations of IDH1 (R132H) and of the tumor suppressor genes, FUBP1 and CIC. The xenografts were highly invasive, exhibiting a distinct migration and growth pattern around neurons, especially in the hippocampus, and following white matter tracts of the corpus callosum with tumor cells accumulating around established vasculature. Although tumors exhibited a high growth fraction in vivo, neither cells from the original patient tumor nor the xenograft exhibited significant growth in vitro over a six-month period. This glioma xenograft is the first to display a pure oligodendroglioma histology and expression of R132H. The unexpected property, that the cells fail to grow in vitro even after passage through the mouse, allows us to uniquely investigate the relationship of this oligodendroglioma with the in vivo microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.